Recent studies have shown that even low amounts of D9-tetrahydrocannbinol (THC) within a cannabidiol (CBD) product can result in positive 11-nor-9-carboxy-D9- tetrahydrocannabinol (THC-COOH; a metabolite of THC) urine drug screens.
Aim: To characterize perceived benefits and challenges experienced by medicinal cannabis users. Methods: An anonymous online survey collected demographics, health information, and open-ended responses from medicinal cannabis users regarding perceptions, motivations,
Background: Anxiety and depressive disorders are highly prevalent. Patients are increasingly using medicinal cannabis products to treat these disorders, but little is known about the effects of medicinal cannabis use on
Abstract: Recent approval of Epidiolex (pharmaceutical cannabidiol/CBD) for the treatment of Lennox Gastaut syndrome (LGS) and Dravet syndrome highlights a therapeutic efficacy of CBD in the treatment of epilepsy.
Introduction. Despite widespread legalization, the impact of medicinal cannabis use on patient level health and quality of life has not been carefully evaluated. The objective of this study was to
Please use this link to access this publication. ABSTRACT Cannabis was legalized for adult use in California in 2016 for individuals 21 and older. Among 18–20-years-olds, who can possess cannabis […]
March 6, 2025
Please use this link to access this publication. ABSTRACT Introduction Pharmaceutically purified oral cannabidiol (CBD) has been recently approved by the US Food and Drug Administration and European Medicines Agency […]
April 19, 2024
Abstract Background: Chronic non-cancer pain (CNCP) is estimated to affect 20% of the adult population. Current United States and Canadian Chronic non-cancer pain guidelines recommend careful reassessment of the risk-benefit ratio […]
June 20, 2025
Abstract Empirical evidence continues to accumulate suggesting cannabidiol (CBD) may have potential as an anxiolytic. Yet, research in the area is insufficient to support strong inferences. Accordingly, there is a […]
October 28, 2021
Abstract Tardive dyskinesia (TD) is a movement disorder that appears after chronic use of drugs that block dopaminergic receptors such as antipsychotics. Besides the motor symptoms, patients with TD also present cognitive deficits. Neuroinflammatory mechanisms could be […]
April 24, 2024
Osteosarcoma is the most frequent primary malignant bone tumor that occurs in children and adolescents. The present study aimed to identify novel therapeutic strategies for osteosarcoma, by assessing the antitumor […]
September 19, 2019
Ceramide levels are elevated in mantle cell lymphoma (MCL) cells following treatment with cannabinoids. Here, we investigated the pathways of ceramide accumulation in the MCL cell line Rec-1 using the […]
Simple Summary It is easy to find success stories on the internet of patients with cancer who seem to benefit from using cannabis products. However, scientific substantiation is usually lacking. […]
October 3, 2024
Please use this link to access this publication. Abstract The utility of cannabinoids and cannabinoid-based products (CBPs) as a pharmacological aid to treat psychiatric disorders in adulthood is still poorly […]
March 25, 2024
Abstract The use of cannabidiol (CBD) among athletes is becoming extensive and frequent. This could be due to the elimination of CBD from the list of prohibited substances by federations […]
April 23, 2024
